Roche Holding AG Stock News

Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.

Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG's experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from Abb

Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.

David Roche, president and global strategist at Independent Strategy, explains what is the “gray zone”, asset allocation in China and his outlook for emerging markets. He speaks on Bloomberg Telev

David Roche of Independent Strategy says the deal will allow borrowing to "go forward well into 2024," among other things.

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncol

It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche H

The debt ceiling crisis is coming down to the wire. We're possibly already out of time to prevent default and just don't know it. UBS estimates a short default could create a 20% bear market and a one

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.

Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.

Investors can find growth plays in many corners of the stock market, but  a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend

Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.

GSK and Roche both outplayed declining Covid-related sales in the first quarter to beat Wall Street's earnings expectations. The post Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarter

Roche Holding AG on Wednesday posted a decline in sales for the first quarter as its diagnostics division suffered from significantly lower demand for Covid-19 tests, and backed its outlook for the ye